Gates Foundation Will Commit $10 Billion for Vaccine Development

Gates Foundation announced commitment of $10 billion over the next decade to help research, develop and deliver vaccines for the world’s poorest countries. The foundation used a model developed by a consortium led by the Institute of International Programs at the Johns Hopkins Bloomberg School of Public Health to project the potential impact of vaccines on childhood deaths over the next 10 years. By significantly scaling up the delivery of life-saving vaccines in developing countries to 90 percent coverage—including new vaccines to prevent severe diarrhea and pneumonia—the model suggests that we could prevent the deaths of some 7.6 million children under 5 from 2010-2019. The foundation also estimates that an additional 1.1 million children could be saved with the rapid introduction of a malaria vaccine beginning in 2014, bringing the total number of potential lives saved to 8.7 million.

If additional vaccines are developed and introduced in this decade—such as for tuberculosis—even more lives could be saved. The new funding announced today is in addition to the $4.5 billion that the Gates Foundation has already committed to vaccine research, development and delivery to date across its entire disease portfolio since its inception.

Recent years have seen the remarkable success stories of vaccine development:

• Record-breaking vaccine access: New WHO data show that global vaccination rates have reached all-time highs, rebounding from years of decline in the 1990s. Between 2000 and 2009, the percentage of children receiving the basic DTP3 vaccine in the poorest countries of the world jumped from 66 percent to 79 percent, the highest on record. The number of people who died of measles worldwide fell by 77 percent between 2000 and 2008, and in Africa, measles deaths fell by 92 percent.
• Improved routine immunization: Partnerships focused on reducing diseases like polio and measles are also helping build a stronger foundation for the delivery of both new and existing vaccines. Trained health workers, proper cold chain function, and surveillance are all necessary to ensure vaccines reach every child who needs them.
• New vaccine introduction: Important new vaccines for the two leading causes of global child deaths—severe diarrhea and pneumonia—are becoming available. Research published this week in The New England Journal of Medicine shows that introducing a rotavirus vaccine in South Africa and Malawi reduced severe diarrhea caused by the virus by more than 60 percent.
• R&D momentum: The vaccine research and development pipeline is more robust than ever. Late-stage trials have begun on a promising vaccine to protect children from malaria, and a new vaccine to prevent meningitis outbreaks in Africa is likely to be introduced this year.

Many of the recent advances in vaccine development and delivery have been driven by public-private partnerships such as the GAVI Alliance and the Rotavirus Vaccine Program at PATH, which coordinate the resources and expertise of vaccine companies, donors, UNICEF, WHO, the World Bank, and developing countries.

The GAVI Alliance—launched at the World Economic Forum 10 years ago this week—has reached 257 million additional children with new and underused vaccines, and prevented 5 million future deaths. In the coming years, GAVI will focus on rapidly introducing vaccines to tackle diarrhea and pneumonia.

Today’s commitment will support a broad spectrum of vaccine-related activities, from basic research to innovations in delivery. However, billions more are needed from other donors to achieve the goal of 90 percent coverage of childhood immunization. Critical funding gaps exist at GAVI and in the global polio and measles programs, and more support is needed for the research and development necessary to produce new vaccines.

Still new funding from donors, governments and the private sector is badly needed to:

• Rapidly scale immunization programs in order to reach all those in need
• Conduct the laboratory research and clinical trials needed to create new vaccines
• Introduce life-saving new vaccines for pneumonia and severe diarrhea, as well as other promising vaccines currently in the development pipeline
• Ensure a steady market for vaccines in developing countries, and an adequate supply from manufacturers